Skip to main content

Abstract

In the present study, we evaluated the anti-inflammatory properties of Lactiplantibacillus plantarum 22A-3 (LP22A3) and attempted to elucidate the underlying molecular mechanism. The oral administration of LP22A3 significantly inhibited body weight reduction and decreased colon shortening and colitis score in mice with dextran sulfate sodium (DSS)-induced colitis. It was demonstrated that the production of the active-form of TGF-β tended to increase in both the intestinal epithelial cells (IECs) of the ileum and serum but not in the colon of non-DSS-treated mice by LP22A3. IL-10 level in serum was also elevated by LP22A3-treatment. The mRNA expression of TGF-β, IL-10 and Foxp3 increased only in the small intestines of LP22A3-treated mice. Both the aldehyde dehydrogenase 1 family member A2 (Aldh1a2) mRNA expression and population of CD103+ dendritic cells (DCs) in the small intestine significantly increased in the LP22A3-treated group. LP22A3 induced TGF-β secretion from the IECs of the small intestine with retinoic acid production probably through TLR2, resulting in an increase in CD103+ DCs and the Foxp3+ Treg population. Both cells secrete a high level of anti-inflammatory cytokines, TGF-β and IL-10 contributing to the protective condition in the intestine and thus making it less susceptible to inflammation. This suggested that oral administration of LP22A-3 may be an alternative therapeutic strategy for IBD.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Lactiplantibacillus plantarum KABP™-023Improved Colitis SymptomsBeneficial
Moderate
Lactiplantibacillus plantarum KABP™-023Increased CD103+ Dendritic Cell CountBeneficial
Moderate
Lactiplantibacillus plantarum KABP™-023Increased Interleukin-10 LevelsBeneficial
Moderate
Lactiplantibacillus plantarum KABP™-023Increased Regulatory T Cell PopulationsBeneficial
Moderate
Lactiplantibacillus plantarum KABP™-023Increased TGF-β LevelsBeneficial
Moderate
Lactiplantibacillus plantarum LP-01Increased CD103+ Dendritic Cell PopulationBeneficial
Moderate
Lactiplantibacillus plantarum LP-01Increased Serum IL-10 LevelsBeneficial
Moderate
Lactiplantibacillus plantarum LP-01Increased Transforming Growth Factor-β LevelsBeneficial
Moderate
Lactiplantibacillus plantarum LP-01Increased Treg Population in the Small IntestineBeneficial
Moderate
Lactiplantibacillus plantarum LP-01Reduced Ulcerative Colitis SymptomsBeneficial
Large
Lactiplantibacillus plantarum LP-1Increased Anti-Inflammatory Cytokines in the Small IntestineBeneficial
Moderate
Lactiplantibacillus plantarum LP-1Increased CD103+ Dendritic Cell PopulationBeneficial
Moderate
Lactiplantibacillus plantarum LP-1Increased Regulatory T Cell PopulationsBeneficial
Moderate
Lactiplantibacillus plantarum LP-1Increased Serum IL-10 LevelsBeneficial
Moderate
Lactiplantibacillus plantarum LP-1Increased TGF-β ProductionBeneficial
Moderate
Lactiplantibacillus plantarum LP-1Reduced Ulcerative Colitis SymptomsBeneficial
Large
Lactiplantibacillus plantarum Lp-115Enhanced Anti-Inflammatory Cytokine SecretionBeneficial
Large
Lactiplantibacillus plantarum Lp-115Improved Colitis SymptomsBeneficial
Moderate
Lactiplantibacillus plantarum Lp-115Increased CD103+ Dendritic Cell CountBeneficial
Moderate
Lactiplantibacillus plantarum Lp-115Increased Regulatory T-CellsBeneficial
Moderate

Pillser helps you make informed health decisions by providing comprehensive, unbiased information about supplements. This includes detailed research on supplement ingredients, their benefits, potential risks, and their overall efficacy. You can contribute by sharing your feedback and suggestions.

Send us an email at support@pillser.com.